N-(3-methylcyclohexyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-methylcyclohexyl)benzamide
• 化学式: C₁₄H₁₉NO
• mdl: MFCD02667977
• 分子量: 217.311
• InChiKey: BSTHPONDLDGVEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 N-(3-methylcyclohexyl)benzamide
  参考文献：
  名称：

  Gutt, Chemische Berichte, 1907, vol. 40, p. 2066

  摘要：

  DOI：

文献信息

• A Direct and Stereoretentive Synthesis of Amides from Cyclic Alcohols
  作者：Deboprosad Mondal、Luca Bellucci、Salvatore D. Lepore

  DOI：10.1002/ejoc.201101165

  日期：2011.12

  Chlorosulfites prepared in situ using thionyl chloride react with nitrile complexes of titanium (IV) fluoride to give a one-pot conversion of alcohols into amides. For the first time, amides are obtained from cyclic alcohols with stereoretention. Critical to the design of these new Ti(IV) reactions has been the use of little explored Ti(IV) nitrile complexes which are thought to chelate chlorosulfites

  使用亚硫酰氯原位制备的亚硫酸盐与氟化钛 (IV) 的腈络合物反应，将醇一锅法转化为酰胺。首次从具有立体保留的环醇中获得酰胺。设计这些新的 Ti(IV) 反应的关键是使用很少探索的 Ti(IV) 腈配合物，这些配合物被认为可以螯合过渡态的氯亚硫酸盐以产生碳正离子，该碳正离子可通过前缘快速被腈亲核试剂捕获侧攻击机制。
• 5-Substitued imidazo[4,5-c]pyridines
  申请人：G.D. Searle & Co.

  公开号：EP0344414A1

  公开（公告）日：1989-12-06

  This invention relates to novel substituted imidazopyridine dervatives having the following formula or a pharmaceuticaly acceptable acid addition salt: wherein R₁ and R₂      are each independently selected from hydrogen; straight or branched chain alkyl of 1 to 15 carbon atoms; cycloalkyl having 3 to 8 carbon atoms; substituted cycloalkyl which can be substituted one or more by alkyl of 1 to 6 carbon atoms; bicycloalkyl having 3 to 8 carbon atoms in each ring; heterocyclicalkyl having 4 to 8 carbon atoms which can be optionally substituted by alkyl of 1 to 6 carbon atoms; heteroaromatic having 5 or 6 carbon atoms which can be optionally substituted by alkyl of 1 to 6 carbon atoms; phenyl; substituted phenyl which can be substituted one or more by a group independently selected from alkyl of 1 to 6 carbon atoms or halogen; straight or branched alkenyl having 3 to 15 carbon atoms with the proviso that the double bond of the alkenyl group cannot be adjacent to the nitrogen; cycloalkenyl having 5 to 8 carbon atoms with the proviso that the double bond cannot be adjacent to the nitrogen; R₁ and R₂ cannot both be hydrogen Y      is phenyl or phenyl substituted once or more than at one or more of the 2, 3, 5 or 6 position of the phenyl ring by substituents independently selected from the group consisting of alkoxy wherein the alkyl is 1 to 6 carbon atoms; halogen wherein the halogen is selected from bromo, fluoro, or chloro; straight or brnached chain alkyl having 1 to 6 carbon atoms; substituted straight or branched chain alkyl which can be substituted one or more by halogen; thioalkyl wherein the alkyl is 1 to 6 carbon atoms; alkoxyalkyl wherein the alkyl groups are each 1 to 6 carbon atoms; hydroxyalkyl wherein the alkyl is 1 to 6 carbon atoms; alkylthioalkyl wherein the alkyl group are each 1 to 6 carbon atoms; cyano; mercaptoalkyl wherein the alkyl is 1 to 6 carbon atoms; hydroxy; amino; alkylamino wherein the alkyl group are each 1 to 6 carbon atoms; and dialkylamino wherein the alkyl group are each 1 to 6 carbon atoms. n      is an integer of 1 to 5. R₃      is a group substituted at one or more of the 4, 6, or 7 positions of the pyridine ring said group being independently selected from hydrogen; alkyl of 1 to 6 carbon atoms; halogen wherein the halogen is selected from bromo, fluoro or chloro; alkoxy wherein the alkyl is 1 to 6 carbon atoms. R₄      is hydrogen or alkyl of 1 to 6 carbon atoms. useful in the treatment of diseases or disorders mediated by platelet-activating factor. This invention relates to pharmaceutical compositions of such substituted imidazopyridines.

  本发明涉及具有下式的新型取代咪唑吡啶防腐剂 或药物可接受的酸加成盐： 其中 R₁和 R₂各自独立地选自氢；1 至 15 个碳原子的直链或支链烷基；3 至 8 个碳原子的环烷基；可被 1 至 6 个碳原子的烷基取代一个或多个的取代环烷基；每个环中有 3 至 8 个碳原子的双环烷基；4 至 8 个碳原子的杂环烷基，可任选被 1 至 6 个碳原子的烷基取代；5 或 6 个碳原子的杂芳基，可任选被 1 至 6 个碳原子的烷基取代；苯基；可被一个或多个独立选自 1 至 6 个碳原子的烷基或卤素的基团取代的取代苯基；具有 3 至 15 个碳原子的直链或支链烯基，但烯基的双键不能与氮相邻；具有 5 至 8 个碳原子的环烯基，但双键不能与氮相邻；R₁ 和 R₂ 不能都是氢。 Y 是苯基或在苯基环的 2、3、5 或 6 位上被取代基取代一次或多次的苯基，取代基 独立选自由以下组成的基团：烷氧基（其中烷基为 1-6 个碳原子）；卤素（其中卤素选 自溴、氟或氯）；具有 1-6 个碳原子的直链或支链烷基；可被卤素取代一次或多次的取代 直链或支链烷基；硫代烷基，其中烷基为 1 至 6 个碳原子；烷氧基烷基，其中烷基各为 1 至 6 个碳原子；羟基烷基，其中烷基为 1 至 6 个碳原子；烷硫基烷基，其中烷基各为 1 至 6 个碳原子；氰基；巯基烷基，其中烷基为 1 至 6 个碳原子；羟基；氨基；烷基氨基，其中烷基各为 1 至 6 个碳原子；以及二烷基氨基，其中烷基各为 1 至 6 个碳原子。 n 是 1 至 5 的整数。 R₃ 是在吡啶环的一个或多个 4、6 或 7 位上被取代的基团，所述基团独立选自氢；1 至 6 个碳原子的烷基；卤素，其中卤素选自溴、氟或氯；烷氧基，其中烷基为 1 至 6 个碳原子。 R₄ 是氢或 1-6 个碳原子的烷基。 用于治疗由血小板活化因子介导的疾病或失调。本发明涉及此类取代咪唑吡啶的药物组合物。
• US5019581A
  申请人：——

  公开号：US5019581A

  公开（公告）日：1991-05-28
• US5227384A
  申请人：——

  公开号：US5227384A

  公开（公告）日：1993-07-13
• US5302601A
  申请人：——

  公开号：US5302601A

  公开（公告）日：1994-04-12